I agree with you that we really just don't know at this point and anxiously wait, but I think we do have some information even if it comes from a lack of information and silence. We are far enough along in the trial that we would know if PFS results for placebo and DCVAX patents showed no difference (average tumor reoccurrence time after surgery, chemo and radiation is 6 months). If that was clearly the case they would have had to tell us the bad news by now . . . so it is either good news or the FDA and NWBO are in a heated debate about whether or not what they are counting as reoccurrence is really reoccurrence. There has been a lot of discussion about that on this board and might account for the temporary screening halt to provide additional data. It might be that they have agreed to disagree at this point so we are now in a situation where we are forced to wait for OS results . . . which will be complicated by the crossover at reoccurrence . . . although if the whole cohort is living longer as Dr. Liau stated in the October 15, 2015 video at some point the FDA has to conceded that the treatment does indeed work. Average OS after surgery, chemo and radiation is somewhere between 14 months to just under 2 years depending on what figures you want to use . . . so it is hard to say if could be there just yet . . . we might be with the Mesenchymal subgroup if this is really a cure for them. The $3 warrant offering was extended a few weeks so I guess we will know very soon if there was a reason for that or they are just stringing us along. Good luck